Bioavailability and pharmacokinetics of cefotaxime in Muscovy ducks

Abstract

The pharmacokinetic profile of cefotaxime following a single intravenous (IV) and intramuscular (IM) injection was studied in Muscovy ducks. Cefotaxime was given at a dose rate of 25 mg/kg b.wt. for both routes. After IV injection, the plasma levels of cefotaxime estimated at 0.08 h was 70.87 μg/ml, which declined gradually and cefotaxime was detected up to 10 h (0.59 μg/ml). The mean values of CL, V dss and t 1/2β of cefotaxime in muscovy ducks were 0.22 l/kg/h, 0.51 l/kg and 1.81 h, respectively. After IM injection, maximum plasma concentration (C max ) was (14.72 μg/ml), time of maximal plasma concentration (t max ) was (2.3 h) and elimination half-life (t 1/2el ) was (1.77 h). Bioavailability following IM injection was 79.61%, and in vitro protein binding percent was 31.48%. A recommended IM dosage for cefotaxime in muscovy ducks would be 30 mg/kg b.wt., repeated at 12 h intervals will provide a therapeutic plasma concentrations exceeding the MIC≤0.5 µg/ml for most susceptible pathogens in ducks.

Bioavailability, pharmacokinetics and tissue residues of cephradine (Atocef Forte®) in healthy and colisepticemic broiler chickens

“…This percent indicated a good absorption of cephradine after oral administration. This value was similar to that recorded for cefotaxime in Muscovy ducks 79.6% (Aboubakr, 2016). Repeated oral administration of 20 mg cephradine/kg b. wt.…”

“…The serum concentration-time curve of cephradine following IV injection showed that cephradine obeyed a two compartments open model. The disposition kinetics of cephradine following a single IV and oral administration (in drinking water) were recorded in table (1) and showed in figure (1). Tissue samples from liver, kidney, spleen, heart, breast muscle, thigh muscle, skin and fats were taken for assaying of residues of cephradine at 24, 48, 72, 96 and 120 h after the last oral dose of the drug from healthy chickens were compared to those in E.coli infected chickens (Table 2).…”